合约开发与生产组织市场－全球产业规模、份额、趋势、机会与预测：按服务类型分類的CMO、按研发阶段分類的CRO、地区和竞争格局，2021-2031年

全球合约开发和生产组织 (CDMO/CMO) 市场预计将从 2025 年的 2,454.7 亿美元成长到 2031 年的 3,638.6 亿美元，复合年增长率为 6.78%。

这些机构为製药业提供从早期药物研发到商业化生产和包装的全方位服务。这一增长主要源于生物製药治疗方法的日益复杂化以及对营运效率的策略性关注。这促使创新企业将生产外包给专业合作伙伴。药物研发领域的强劲投资进一步强化了对外部专业知识的依赖。根据欧洲製药工业协会联合会 (EFPIA) 估计，到 2024 年，以研发为基础的製药业将在欧洲的研发领域投资 550 亿欧元，从而产生对技术外包服务的巨大需求。

然而，市场在供应链韧性和监管合规性方面面临严峻挑战。日益紧张的地缘政治局势以及法律规范的变化迫使企业重组其全球供应链网络。这种重组往往会导致产能受限和营运成本增加，进而可能造成计划延长并扰乱基本药物的供应。

市场驱动因素

生物製药和先进治疗药物的快速扩张正在从根本上改变市场格局，并引发对专业化生产能力的激增需求。随着製药公司专注于开发抗体药物复合体（ADC）和GLP-1促效剂等复杂治疗方法，它们越来越依赖外部合作伙伴来克服技术挑战并扩大生产规模。这一趋势在产业为确保产能而进行的重组工作中显而易见。根据DCAT价值链洞察报告，截至2024年12月，最大的市场动态是诺和诺德控股斥资165亿美元收购Catalent，以支持其减肥药的生产。主要企业正从这项需求中直接获益，三星生物製剂在订单生物製药生产订单的增加。

同时，依赖合约合作伙伴提供端到端开发支援的小型新兴生物技术公司正在对市场产生重大影响。这些小规模公司通常缺乏管理整个药物生命週期的内部基础设施，因此依赖合约研发生产机构（CDMO）来完成从临床试验到商业化的整个流程。该领域的活动与资金筹措环境密切相关，而近期融资环境呈现改善趋势。正如龙沙在2025年4月发布的2024财年年度报告创业投资所述，生物製药领域的资金筹措已显着復苏，较去年同期成长超过20%。资金的流入使新兴创新者能够与服务供应商续约，并透过维持强大的早期计划储备来重振整个契约製造产业。

市场挑战

地缘政治紧张局势以及由此产生的严格监管要求，是全球合约研发（CDMO）市场成长的主要障碍。随着各国政府加强对国家安全和供应链自主权的法律体制，製药创新公司被迫重组现有的生产网络。这种被迫放弃既有伙伴关係的做法，造成了营运瓶颈，因为与整合服务供应商脱钩会扰乱计划的连续性，并推高采购成本。

这些干扰因素直接阻碍了市场发展势头，导致临床试验进度延误，以及其他地区产能受限。这种高度依赖性凸显了快速多元化的难度。根据2024年生物技术创新组织的数据，约79%的受访生物製药公司至少有一项合约或产品与中国的研发和生产合作伙伴有关。如此高的地区依赖性意味着供应链转型是一个资本密集且缓慢的过程，资金被用于风险规避而非新的研发项目，从而有效地阻碍了市场扩张。

市场趋势

人工智慧 (AI)数位双胞胎技术的融合正在迅速改变契约製造生产环境。这使得供应商能够从简单的执行伙伴转型为策略创新者。透过利用预测演算法和虚拟製程建模，合约开发和生产组织 (CDMO) 可以显着缩短技术转移时间，并在实际生产开始前优化批次产量。这种数位化成熟度正成为一项关键的竞争优势，直接满足了产业在复杂治疗方法对效率和风险降低的需求。根据《合约製药》(Contract Pharma) 2025 年 9 月号报导，一项调查发现，49% 的受访者表示，营运效益是他们从智慧製造策略中寻求的主要价值。

同时，由于监管压力和客户对范围3减排排放的需求，采用永续的绿色化学实践已成为市场参与企业的关键要求。契约製造製造商正积极重新设计合成路线并采用再生能源来源，以配合其製药合作伙伴的脱碳目标。然而，儘管有此策略重点，但对许多供应商而言，转型仍需要大量资金投入，且在营运上充满挑战。根据CPHI Online在2025年7月报道，Pharmapack 2025策略洞察与研究调查发现，76%的受访者认为资源限制是有效实施永续性倡议的主要障碍。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球合约研发生产组织（CDMO/CMO）市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按服务类型分類的合约生产商（原料原料药生产、最终剂型（FDF）开发与生产、二级包装）
  • 依研究阶段分類的CRO（非临床试验、I期、II期、III期、IV期）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美合约研发生产组织（CDMO/CMO）市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲合约研发生产机构（CDMO/CMO）市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区合约研发生产力机构（CDMO/CMO）市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲合约研发生产力组织（CDMO/CMO）市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲合约研发生产机构（CDMO/CMO）市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球合约开发与生产组织（CDMO/CMO）市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Lonza
• Catalent
• Thermo Fisher Scientific
• Samsung Biologics
• WuXi Biologics
• Recipharm
• Boehringer Ingelheim BioXcellence
• Jubilant Biosys/Jubilant Pharmova
• Fareva
• Rentschler Biopharma

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Contract Development & Manufacturing Organization (CDMO and CMO) Market is projected to expand from USD 245.47 Billion in 2025 to USD 363.86 Billion by 2031, reflecting a Compound Annual Growth Rate of 6.78%. These organizations provide comprehensive services to the pharmaceutical sector, encompassing everything from early-stage drug development to commercial production and packaging. This growth is primarily driven by the rising complexity of biologic therapies and a strategic emphasis on operational efficiency, which prompts innovators to entrust manufacturing to specialized partners. This reliance on external expertise is bolstered by strong funding in drug discovery; the European Federation of Pharmaceutical Industries and Associations estimated that the research-based pharmaceutical industry invested 55 billion Euros in R&D in Europe in 2024, generating substantial demand for outsourced technical services.

However, the market faces significant hurdles regarding supply chain resilience and regulatory compliance. Escalating geopolitical tensions and shifting legislative frameworks are compelling companies to reorganize their global supply networks. This restructuring often results in capacity constraints and higher operational costs, which can delay project timelines and hinder the delivery of essential medicines.

Market Driver

The rapid expansion of biologics and Advanced Therapy Medicinal Products is fundamentally transforming the market, creating a surge in demand for specialized manufacturing capabilities. As pharmaceutical companies focus on developing complex modalities like antibody-drug conjugates and GLP-1 agonists, they increasingly rely on external partners to overcome technical challenges and scale production. This trend is highlighted by significant sector consolidation to secure capacity; according to DCAT Value Chain Insights in December 2024, the largest market move was Novo Holdings' $16.5 billion acquisition of Catalent to support obesity treatment manufacturing. Major players are seeing direct financial benefits from this demand, with Samsung Biologics reporting a full-year consolidated revenue of KRW 4.55 trillion in January 2025, a 23% increase driven largely by expanded biologic production orders.

Simultaneously, the market is heavily influenced by small and emerging biotech companies that depend on contract partners for end-to-end development support. These smaller entities often lack the internal infrastructure to manage the entire drug lifecycle and rely on CDMOs to progress from clinical trials to commercialization. This segment's activity is closely linked to capital availability, which has recently improved. As noted in Lonza's 'Annual Report 2024' released in April 2025, venture capital funding in the biopharma sector rebounded significantly, showing over 20% year-on-year investment growth. This influx of capital allows emerging innovators to re-engage service providers, maintaining a robust pipeline of early-stage projects that fuels the broader contract manufacturing industry.

Market Challenge

Geopolitical tensions and the consequent need for strict regulatory compliance present a major barrier to the growth of the Global Contract Development and Manufacturing Organization market. As governments enforce tighter legislative frameworks regarding national security and supply chain independence, pharmaceutical innovators face intense pressure to restructure their existing manufacturing networks. This forced migration from established partnerships creates operational bottlenecks, as decoupling from integrated service providers disrupts project continuity and inflates procurement costs.

These disruptions directly impede market momentum by delaying clinical timelines and limiting available production capacity in alternative regions. The extent of this dependency highlights the difficulty of rapid diversification. Data from the Biotechnology Innovation Organization in 2024 revealed that approximately 79 percent of responding biopharmaceutical companies held at least one contract or product linked to a development or manufacturing partner in China. Such high reliance on specific geographies means that shifting supply chains is a capital-intensive and slow process, effectively stalling broader market expansion as funds are diverted toward risk mitigation rather than new development programs.

Market Trends

The Integration of Artificial Intelligence and Digital Twin Technology is rapidly reshaping the operational landscape of contract manufacturing, allowing providers to evolve from simple execution partners into strategic technical innovators. By utilizing predictive algorithms and virtual process modeling, CDMOs can significantly shorten technology transfer timelines and optimize batch yields before physical production begins. This digital maturity is becoming a key competitive factor, directly addressing the industry's need for efficiency and risk reduction in complex modalities. According to a September 2025 article in Contract Pharma titled 'AI in Pharma Manufacturing: Trends & Applications Shortening Timelines', a study indicated that 49% of respondents viewed operational benefits as the primary value sought from smart manufacturing strategies.

In parallel, the Implementation of Sustainable Green Chemistry Practices has become a critical requirement for market participants, driven by increasing regulatory pressure and client mandates to reduce Scope 3 emissions. Contract organizations are actively re-engineering synthetic pathways and adopting renewable energy sources to align with the decarbonization goals of their pharmaceutical partners. Despite this strategic focus, the transition remains capital-intensive and operationally challenging for many providers. As reported by CPHI Online in July 2025, the Pharmapack 2025 Strategic Insights & Research survey revealed that 76% of respondents cited resource constraints as the dominant barrier to effectively implementing sustainability initiatives.

Key Market Players

• Lonza
• Catalent
• Thermo Fisher Scientific
• Samsung Biologics
• WuXi Biologics
• Recipharm
• Boehringer Ingelheim BioXcellence
• Jubilant Biosys / Jubilant Pharmova
• Fareva
• Rentschler Biopharma

Report Scope

In this report, the Global Contract Development & Manufacturing Organization (CDMO and CMO) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Contract Development & Manufacturing Organization (CDMO and CMO) Market, By Service Type CMO

• Active Pharmaceutical Ingredient (API) Manufacturing
• Finished Dosage Formulation (FDF) Development and Manufacturing
• Secondary Packaging

Contract Development & Manufacturing Organization (CDMO and CMO) Market, By Research Phase CRO

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Contract Development & Manufacturing Organization (CDMO and CMO) Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Contract Development & Manufacturing Organization (CDMO and CMO) Market.

Available Customizations:

Global Contract Development & Manufacturing Organization (CDMO and CMO) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service Type CMO (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging)
  • 5.2.2. By Research Phase CRO (Pre-clinical, Phase I, Phase II, Phase III, Phase IV)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service Type CMO
  • 6.2.2. By Research Phase CRO
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service Type CMO
      • 6.3.1.2.2. By Research Phase CRO
  • 6.3.2. Canada Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service Type CMO
      • 6.3.2.2.2. By Research Phase CRO
  • 6.3.3. Mexico Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service Type CMO
      • 6.3.3.2.2. By Research Phase CRO

7. Europe Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service Type CMO
  • 7.2.2. By Research Phase CRO
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service Type CMO
      • 7.3.1.2.2. By Research Phase CRO
  • 7.3.2. France Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service Type CMO
      • 7.3.2.2.2. By Research Phase CRO
  • 7.3.3. United Kingdom Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service Type CMO
      • 7.3.3.2.2. By Research Phase CRO
  • 7.3.4. Italy Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service Type CMO
      • 7.3.4.2.2. By Research Phase CRO
  • 7.3.5. Spain Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service Type CMO
      • 7.3.5.2.2. By Research Phase CRO

8. Asia Pacific Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service Type CMO
  • 8.2.2. By Research Phase CRO
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service Type CMO
      • 8.3.1.2.2. By Research Phase CRO
  • 8.3.2. India Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service Type CMO
      • 8.3.2.2.2. By Research Phase CRO
  • 8.3.3. Japan Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service Type CMO
      • 8.3.3.2.2. By Research Phase CRO
  • 8.3.4. South Korea Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service Type CMO
      • 8.3.4.2.2. By Research Phase CRO
  • 8.3.5. Australia Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service Type CMO
      • 8.3.5.2.2. By Research Phase CRO

9. Middle East & Africa Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service Type CMO
  • 9.2.2. By Research Phase CRO
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service Type CMO
      • 9.3.1.2.2. By Research Phase CRO
  • 9.3.2. UAE Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service Type CMO
      • 9.3.2.2.2. By Research Phase CRO
  • 9.3.3. South Africa Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service Type CMO
      • 9.3.3.2.2. By Research Phase CRO

10. South America Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service Type CMO
  • 10.2.2. By Research Phase CRO
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service Type CMO
      • 10.3.1.2.2. By Research Phase CRO
  • 10.3.2. Colombia Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service Type CMO
      • 10.3.2.2.2. By Research Phase CRO
  • 10.3.3. Argentina Contract Development & Manufacturing Organization (CDMO and CMO) Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service Type CMO
      • 10.3.3.2.2. By Research Phase CRO

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Contract Development & Manufacturing Organization (CDMO and CMO) Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Lonza
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Catalent
• 15.3. Thermo Fisher Scientific
• 15.4. Samsung Biologics
• 15.5. WuXi Biologics
• 15.6. Recipharm
• 15.7. Boehringer Ingelheim BioXcellence
• 15.8. Jubilant Biosys / Jubilant Pharmova
• 15.9. Fareva
• 15.10. Rentschler Biopharma

16. Strategic Recommendations

17. About Us & Disclaimer